Carotuximab, identified as TRC105 and DE-122, represents a unique antibody-drug conjugate therapeutic currently being studied for combating various cancerous conditions. This particular molecule binds to a specific antigen, found on malignant cells, administering a potent cytotoxic payload directly to the tumor area. Preliminary clinical assessment

Vadastuximab tedelpar antibody-drug conjugate representing a crucial advancement in the treatment of acute myeloid leukemia (AML). This pioneering therapy precisely targets CD33, a protein frequently present on leukemic populations. The action involves binding to CD33, leading to both direct cytotoxicity and improved immune-mediated elimination of

The arrival of amivantamab offers a exciting step forward for people battling cancers with c-MET overexpression. This novel antibody, a selective blocker of dual MET kinase and also human epidermal growth factor receptor 2 (HER2), showed encouraging effectiveness in patient assessments, particularly in patients whose tumors possess detectable c-MET